眾興菌業(002772.SZ):2022年擬向金融機構申請不超20億元綜合授信額度
格隆匯3月23日丨眾興菌業(002772.SZ)公佈,公司於2022年03月23日召開第四屆董事會第十二次會議審議通過了《關於預計2022年向銀行等金融機構申請綜合授信額度的議案》,為滿足公司生產經營和業務發展的需要,拓寬投融資渠道並結合公司實際情況,2022年公司(含合併報表範圍內子公司)擬向中國工商銀行、中國農業銀行、中國銀行、中國建設銀行、交通銀行、中國郵政儲蓄銀行、中國農業發展銀行、中國進出口銀行、中國民生銀行、上海浦東發展銀行、中信銀行、華夏銀行、甘肅銀行、蘭州銀行、農村合作銀行及融資租賃公司等金融機構申請不超過20億元的綜合授信額度,有效期限自股東大會審議通過後12個月內,並在有效期限內額度可循環使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.